Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)

A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to Either the Same or Alternate Type of Vaccine, Adjuvanted or Non-adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV or QIV), Administered to Subjects Previously Vaccinated in Trial V118_05 (NCT01964989)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02583256

Enrollment

1601

Registered

2015-10-22

Start date

2016-01-29

Completion date

2017-05-09

Last updated

2019-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Keywords

Influenza Vaccine, MF59 adjuvant

Brief summary

Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously vaccinated in Trial V118\_05. Subjects will receive either the Same or Alternate Type of Vaccine.

Interventions

BIOLOGICALAdjuvanted QIV (aQIV)

Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)

BIOLOGICALNon-adjuvanted QIV

Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

12 Months to 7 Years

Healthy volunteers

Yes

Inclusion criteria

In order to participate in this study, all subjects must meet ALL of the inclusion criteria described. * Subject's parent/legal guardian has voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry. * Male or female subject who has completed their Visit 13 (Study Day 366 for non-naïve subjects) or clinic Visit 15 (Day 390 for naïve subjects) in parent trial V118\_05. * For naïve subjects in parent trial V118\_05 to have received two doses of the same study vaccine (i.e. 2 doses of aQIV or 2 doses of QIV).

Exclusion criteria

* Previous immunization with any influenza vaccine (licensed or investigational) within 6 months prior to enrollment. * Subjects with a clinical condition representing a contraindication to intramuscular vaccination or blood draws. * Unwillingness of the parent(s)/ legal guardian(s) of the subject to refuse to participate in another clinical trial while enrolled in V118-05E3. Additional eligibility criteria may be discussed by contacting the site.

Design outcomes

Primary

Measure	Time frame	Description
Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis	Day 22	GMT and 95% confidence interval (CI) were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.
Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis	Day 22	GMT and 95% CI were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Secondary

Measure	Time frame	Description
Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	Day 1, Day 22	The percentage of subjects achieving seroconversion at Day 22 after vaccination is reported against homologous strains. Seroconversion was defined in subjects seronegative at baseline (i.e. HI titer \<1:10 on Day 1) as postvaccination HI titer ≥1:40 and defined in subjects seropositive at baseline (i.e. HI titer ≥1:10 on Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.
Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	Day 22, Day 181	The GMR is the geometric mean of the fold increase in HI titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed against homologous strains using ANCOVA with study specific covariates. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.
Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	Day 22, Day 181	The percentage of subjects achieving HI titer ≥1:40 at Day 22 and Day 181 after vaccination is reported against homologous strains. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.
Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	Day 22	The percentage of subjects achieving HI Titers ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 at Day 22 after vaccination is reported against homologous strains. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.
Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	Day 1, Day 22, Day 181	GMT and 95% CI were analyzed for Day 22 for the heterologous strains using ANCOVA with study specific covariates. The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B/ Victoria lineage strain, B/Malaysia/2506/2004.
Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	Day 22/Day 1 and Day 181/Day 1	The GMR is the geometric mean of the fold increase in HI titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed for the heterologous strains using ANCOVA with study specific covariates. The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B Victoria lineage strain, B/Malaysia/2506/2004.
Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	Day 22, Day 181	The percentage of subjects achieving HI titer ≥1:40 at Day 22 and Day 181 after vaccination and the percentage of subject who experienced seroconversion is reported for homologous strains. Seroconversion was defined in subjects seronegative at baseline (i.e. HI titer \<1:10 on Day 1) as post-vaccination HI titer ≥1:40 and defined in subjects seropositive at baseline (i.e. HI titer ≥1:10 on Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer. The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B/Victoria lineage strain, B/Malaysia/2506/2004.
Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	Day 1, Day 22, Day 181	To further characterize immune response, MN GMT and 95% CI were analyzed for Day 1, Day 22, and Day 181 against homologous strains. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.
Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	Day 22/Day 1 and Day 181/Day 1	The GMR is the geometric mean of the fold increase in MN titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed for the homologous strains using ANCOVA with study specific covariates. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.
Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)	Day 22	GMT and 95% CI were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.
Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	Day 22/Day 1 and Day 181/Day 1	The GMR is the geometric mean of the fold increase in anti-NA titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed against homologous strains using ANCOVA with study specific covariates. Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.
Safety Endpoint: Percentage of Subjects With Solicited AEs	Day 1 to Day 7 after vaccination	Safety of revaccination was assessed in terms of percentage of subjects reporting solicited AEs up to 7 days after vaccination.
Safety Endpoint: Percentage of Subjects With Unsolicited AEs	Day 1 to Day 366	Safety of revaccination was assessed in terms of percentage of subjects reporting unsolicited AEs during the overall study period (Day 1 to Day 366).
Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	Day 1 to Day 366	Safety of revaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCD, AESI and medically attended AE. Each subject was followed for a period of 12 months after receipt of the study vaccine. NOCDs include AEs that represents a new diagnosis of a chronic medical condition that was not present or suspected in a subject prior to study enrollment. AESIs include potentially immune-mediated disorders which were reported by the investigators.
Safety Endpoint: Percentage of Subjects With Diagnosis of Failure to Thrive or Short Stature	Day 1 to Day 366	Safety of revaccination was assessed in terms of percentage of subjects reporting diagnosis of failure to thrive or short stature up to 12 months after last vaccination.
Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	Day 1 to Day 366	Safety of revaccination was assessed in terms of percentage of subjects reporting otitis media, or pneumonia, or influenza-like illness up to 12 months after last vaccination.
Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	Day 22, Day 181	The percentage of subjects achieving MN titer ≥1:20, ≥1:40, ≥1:80 ≥1:160, ≥1:320 and ≥1:640 at Day 22 and Day 181 after vaccination is reported against homologous strains. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.
Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	Day 22, Day 181	The percentage of subjects achieving anti-NA titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 after vaccination is reported against homologous strains Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.
Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	Day 1, Day 22, Day 181	To further characterize immune response, adjusted anti-NA GMT and 95% CI were analyzed for Day 1, Day 22, and Day 181 against homologous strains. Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.
Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	Day 181	GMT and 95% CI were analyzed for Day 181 against homologous strains using ANCOVA with study specific covariates. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Countries

Finland, Philippines, Thailand

Participant flow

Recruitment details

This study was conducted at 17 sites in total; 9 sites in Finland, 4 sites in the Philippines and 4 sites in Thailand.

Pre-assignment details

All enrolled subjects were included in the study.

Participants by arm

Arm	Count
aQIV/aQIV Subjects previously vaccinated with aQIV followed one year later by aQIV Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)	403
aQIV/QIV Subjects previously vaccinated with aQIV followed one year later by QIV Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)	403
QIV/aQIV Subjects previously vaccinated with QIV followed one year later by aQIV Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)	402
QIV/QIV Subjects previously vaccinated with QIV followed one year later by QIV Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)	393
Total	1,601

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Overall Study	Administrative/Other	2	0	1	2
Overall Study	Lost to Follow-up	1	1	0	1
Overall Study	Withdrawal by Subject	0	1	1	0

Baseline characteristics

Characteristic	aQIV/aQIV	aQIV/QIV	QIV/aQIV	QIV/QIV	Total
Age, Continuous	54.4 months STANDARD_DEVIATION 17.12	52.3 months STANDARD_DEVIATION 17.02	53.4 months STANDARD_DEVIATION 17.32	53.3 months STANDARD_DEVIATION 17.3	53.0 months STANDARD_DEVIATION 16.91
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	402 Participants	403 Participants	402 Participants	392 Participants	1599 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized Asian	364 Participants	364 Participants	362 Participants	355 Participants	1445 Participants
Race/Ethnicity, Customized Black or African American	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized Other	1 Participants	3 Participants	3 Participants	3 Participants	10 Participants
Race/Ethnicity, Customized White	38 Participants	36 Participants	37 Participants	35 Participants	146 Participants
Region of Enrollment Finland	39 Participants	39 Participants	39 Participants	38 Participants	155 Participants
Region of Enrollment Philippines	210 Participants	211 Participants	213 Participants	212 Participants	846 Participants
Region of Enrollment Thailand	154 Participants	153 Participants	150 Participants	143 Participants	600 Participants
Risk Status At risk	10 Participants	20 Participants	18 Participants	13 Participants	61 Participants
Risk Status Not at risk	393 Participants	383 Participants	384 Participants	380 Participants	1540 Participants
Sex: Female, Male Female	197 Participants	189 Participants	206 Participants	178 Participants	770 Participants
Sex: Female, Male Male	206 Participants	214 Participants	196 Participants	215 Participants	831 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	0 / 403	0 / 403	0 / 402	0 / 393
other Total, other adverse events	289 / 403	269 / 403	274 / 402	229 / 393
serious Total, serious adverse events	10 / 403	11 / 403	7 / 402	8 / 393

Outcome results

Primary

Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis

GMT and 95% confidence interval (CI) were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 22

Population: Immunogenicity per protocol set (PPS) consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop reverse transcription polymerase chain reaction(RT-PCR) confirmed influenza infection between baseline and Visit 2.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
aQIV/aQIV	Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis	A/H1N1	1219.00 titer
aQIV/aQIV	Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis	A/H3N2	2355.52 titer
aQIV/aQIV	Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis	B/Yamagata	276.23 titer
aQIV/aQIV	Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis	B/Victoria	388.35 titer
aQIV/QIV	Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis	B/Victoria	328.42 titer
aQIV/QIV	Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis	A/H1N1	1020.89 titer
aQIV/QIV	Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis	B/Yamagata	232.82 titer
aQIV/QIV	Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis	A/H3N2	2529.83 titer

Comparison: Comparison performed for strain A/H1N1.95% CI: [1.1, 1.3]

Comparison: Comparison performed for strain A/H3N2.95% CI: [0.9, 1]

Comparison: Comparison performed for strain B/Yamagata.95% CI: [1.1, 1.3]

Comparison: Comparison performed for strain B/Victoria.95% CI: [1.1, 1.3]

Primary

Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis

GMT and 95% CI were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 22

Population: The immunogenicity full analysis set (FAS) consisting of all subjects who received a study vaccination and provided immunogenicity data at both Visit 1 (baseline) and at least one post-vaccination visit.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
aQIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis	A/H1N1	1218.91 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis	A/H3N2	2345.71 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis	B/Yamagata	274.75 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis	B/Victoria	387.35 titer
aQIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis	B/Victoria	326.68 titer
aQIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis	A/H1N1	1023.37 titer
aQIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis	B/Yamagata	230.51 titer
aQIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis	A/H3N2	2521.60 titer

Comparison: Comparison performed for strain A/H1N1.95% CI: [1.1, 1.3]

Comparison: Comparison performed for strain A/H3N2.95% CI: [0.9, 1]

Comparison: Comparison performed for strain B/Yamagata.95% CI: [1.1, 1.3]

Comparison: Comparison performed for strain B/Victoria.95% CI: [1.1, 1.3]

Secondary

Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains

The GMR is the geometric mean of the fold increase in anti-NA titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed against homologous strains using ANCOVA with study specific covariates. Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 22/Day 1 and Day 181/Day 1

Population: The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
aQIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N1 (Day 22/Day 1)	5.40 ratio
aQIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N1 (Day 181/Day 1)	3.95 ratio
aQIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N2 (Day 22/Day 1)	4.51 ratio
aQIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N2 (Day 181/Day 1)	2.45 ratio
aQIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 22/Day 1)	5.75 ratio
aQIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 181/Day 1)	3.29 ratio
aQIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 22/Day 1)	6.81 ratio
aQIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 181/Day 1)	3.05 ratio
aQIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 181/Day 1)	2.70 ratio
aQIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 22/Day 1)	5.59 ratio
aQIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N1 (Day 181/Day 1)	2.63 ratio
aQIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 181/Day 1)	3.40 ratio
aQIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 22/Day 1)	7.15 ratio
aQIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N2 (Day 181/Day 1)	2.74 ratio
aQIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N2 (Day 22/Day 1)	5.18 ratio
aQIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N1 (Day 22/Day 1)	5.02 ratio
QIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 22/Day 1)	7.14 ratio
QIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N2 (Day 22/Day 1)	6.13 ratio
QIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N2 (Day 181/Day 1)	2.50 ratio
QIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 22/Day 1)	5.69 ratio
QIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 181/Day 1)	2.32 ratio
QIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 181/Day 1)	3.09 ratio
QIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N1 (Day 22/Day 1)	5.70 ratio
QIV/aQIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N1 (Day 181/Day 1)	3.22 ratio
QIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N2 (Day 22/Day 1)	4.84 ratio
QIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N2 (Day 181/Day 1)	1.79 ratio
QIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N1 (Day 181/Day 1)	1.39 ratio
QIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	N1 (Day 22/Day 1)	3.83 ratio
QIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 22/Day 1)	3.95 ratio
QIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 181/Day 1)	2.21 ratio
QIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 22/Day 1)	5.18 ratio
QIV/QIV	Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 181/Day 1)	1.77 ratio

Secondary

Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains

To further characterize immune response, adjusted anti-NA GMT and 95% CI were analyzed for Day 1, Day 22, and Day 181 against homologous strains. Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 1, Day 22, Day 181

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
aQIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 1)	290.06 titer
aQIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 181)	727.17 titer
aQIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 22)	3175.99 titer
aQIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N1 (Day 1)	1174.69 titer
aQIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 181)	1424.38 titer
aQIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N1 (Day 181)	2477.65 titer
aQIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N2 (Day 1)	204.59 titer
aQIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N1 (Day 22)	3403.72 titer
aQIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 22)	1288.67 titer
aQIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N2 (Day 22)	915.19 titer
aQIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N2 (Day 181)	505.91 titer
aQIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 1)	497.11 titer
aQIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N1 (Day 22)	3161.01 titer
aQIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 1)	548.92 titer
aQIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N2 (Day 1)	289.86 titer
aQIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 181)	1587.86 titer
aQIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 1)	282.17 titer
aQIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 22)	3336.65 titer
aQIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N1 (Day 1)	1209.21 titer
aQIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N2 (Day 181)	565.69 titer
aQIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N2 (Day 22)	1050.44 titer
aQIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N1 (Day 181)	1649.89 titer
aQIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 181)	596.62 titer
aQIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 22)	1250.88 titer
QIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 22)	3331.87 titer
QIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N1 (Day 1)	230.09 titer
QIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N1 (Day 22)	3588.43 titer
QIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N1 (Day 181)	2018.32 titer
QIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N2 (Day 1)	86.08 titer
QIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N2 (Day 22)	1242.36 titer
QIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N2 (Day 181)	516.51 titer
QIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 1)	306.48 titer
QIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 181)	1443.37 titer
QIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 1)	148.35 titer
QIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 22)	1275.06 titer
QIV/aQIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 181)	511.73 titer
QIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N2 (Day 181)	369.04 titer
QIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N2 (Day 22)	980.87 titer
QIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N1 (Day 1)	182.80 titer
QIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 1)	126.07 titer
QIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N2 (Day 1)	86.34 titer
QIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N1 (Day 181)	870.73 titer
QIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 181)	391.23 titer
QIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 22)	883.66 titer
QIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 22)	2418.50 titer
QIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 1)	237.96 titer
QIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	N1 (Day 22)	2410.65 titer
QIV/QIV	Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 181)	1030.77 titer

Secondary

Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains

The GMR is the geometric mean of the fold increase in HI titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed against homologous strains using ANCOVA with study specific covariates. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 22, Day 181

Population: The immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
aQIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H1N1 (Day 22/Day 1)	7.69 ratio
aQIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H1N1 (Day 181/Day 1)	3.11 ratio
aQIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H3N2 (Day 22/Day 1)	9.02 ratio
aQIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H3N2 (Day 181/Day 1)	5.44 ratio
aQIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Yamagata (Day 22/Day 1)	7.81 ratio
aQIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Yamagata (Day 181/Day 1)	2.74 ratio
aQIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Victoria (Day 22/Day 1)	7.86 ratio
aQIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Victoria (Day 181/Day 1)	2.59 ratio
aQIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Yamagata (Day 181/Day 1)	2.44 ratio
aQIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Yamagata (Day 22/Day 1)	6.58 ratio
aQIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H1N1 (Day 181/Day 1)	2.61 ratio
aQIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Victoria (Day 181/Day 1)	2.33 ratio
aQIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Victoria (Day 22/Day 1)	6.64 ratio
aQIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H3N2 (Day 181/Day 1)	5.50 ratio
aQIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H3N2 (Day 22/Day 1)	9.69 ratio
aQIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H1N1 (Day 22/Day 1)	6.44 ratio
QIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Victoria (Day 22/Day 1)	6.70 ratio
QIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H3N2 (Day 22/Day 1)	9.08 ratio
QIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H3N2 (Day 181/Day 1)	4.72 ratio
QIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Yamagata (Day 22/Day 1)	6.26 ratio
QIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Yamagata (Day 181/Day 1)	2.07 ratio
QIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Victoria (Day 181/Day 1)	2.12 ratio
QIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H1N1 (Day 22/Day 1)	7.61 ratio
QIV/aQIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H1N1 (Day 181/Day 1)	2.72 ratio
QIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H3N2 (Day 22/Day 1)	8.54 ratio
QIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H3N2 (Day 181/Day 1)	4.67 ratio
QIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H1N1 (Day 181/Day 1)	1.95 ratio
QIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	A/H1N1 (Day 22/Day 1)	5.47 ratio
QIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Yamagata (Day 22/Day 1)	4.41 ratio
QIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Victoria (Day 181/Day 1)	1.61 ratio
QIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Victoria (Day 22/Day 1)	4.94 ratio
QIV/QIV	Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains	B/Yamagata (Day 181/Day 1)	1.60 ratio

Secondary

Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains

The GMR is the geometric mean of the fold increase in HI titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed for the heterologous strains using ANCOVA with study specific covariates. The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B Victoria lineage strain, B/Malaysia/2506/2004.

Time frame: Day 22/Day 1 and Day 181/Day 1

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
aQIV/aQIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	A/H3N2 (Day 22/Day 1)	14.67 ratio
aQIV/aQIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	A/H3N2 (Day 181/Day 1)	5.31 ratio
aQIV/aQIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	B/Victoria (Day 181/Day 1)	4.38 ratio
aQIV/aQIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	B/Victoria (Day 22/Day 1)	13.40 ratio
aQIV/QIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	A/H3N2 (Day 181/Day 1)	5.42 ratio
aQIV/QIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	A/H3N2 (Day 22/Day 1)	14.55 ratio
aQIV/QIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	B/Victoria (Day 22/Day 1)	10.18 ratio
aQIV/QIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	B/Victoria (Day 181/Day 1)	3.50 ratio
QIV/aQIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	A/H3N2 (Day 181/Day 1)	5.63 ratio
QIV/aQIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	B/Victoria (Day 22/Day 1)	11.60 ratio
QIV/aQIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	A/H3N2 (Day 22/Day 1)	13.40 ratio
QIV/aQIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	B/Victoria (Day 181/Day 1)	3.17 ratio
QIV/QIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	A/H3N2 (Day 22/Day 1)	12.63 ratio
QIV/QIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	A/H3N2 (Day 181/Day 1)	4.68 ratio
QIV/QIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	B/Victoria (Day 22/Day 1)	8.39 ratio
QIV/QIV	Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains	B/Victoria (Day 181/Day 1)	2.29 ratio

Secondary

Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains

The GMR is the geometric mean of the fold increase in MN titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed for the homologous strains using ANCOVA with study specific covariates. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 22/Day 1 and Day 181/Day 1

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
aQIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H1N1 (Day 22/Day 1)	11.85 ratio
aQIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H1N1 (Day 181/Day 1)	3.67 ratio
aQIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H3N2 (Day 22/Day 1)	28.19 ratio
aQIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H3N2 (Day 181/Day 1)	10.63 ratio
aQIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 22/Day 1)	14.11 ratio
aQIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 181/Day 1)	3.97 ratio
aQIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 22/Day 1)	9.43 ratio
aQIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 181/Day 1)	3.25 ratio
aQIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H3N2 (Day 181/Day 1)	10.93 ratio
aQIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H1N1 (Day 22/Day 1)	12.07 ratio
aQIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 22/Day 1)	9.20 ratio
aQIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H1N1 (Day 181/Day 1)	3.66 ratio
aQIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 181/Day 1)	2.77 ratio
aQIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 22/Day 1)	10.95 ratio
aQIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H3N2 (Day 22/Day 1)	33.88 ratio
aQIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 181/Day 1)	3.84 ratio
QIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 181/Day 1)	2.51 ratio
QIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 22/Day 1)	8.97 ratio
QIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H1N1 (Day 22/Day 1)	15.73 ratio
QIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H3N2 (Day 181/Day 1)	10.99 ratio
QIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 22/Day 1)	8.99 ratio
QIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 181/Day 1)	3.07 ratio
QIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H1N1 (Day 181/Day 1)	3.47 ratio
QIV/aQIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H3N2 (Day 22/Day 1)	25.57 ratio
QIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H1N1 (Day 181/Day 1)	2.08 ratio
QIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H3N2 (Day 22/Day 1)	23.93 ratio
QIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H3N2 (Day 181/Day 1)	8.72 ratio
QIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 22/Day 1)	7.18 ratio
QIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Yamagata (Day 181/Day 1)	2.08 ratio
QIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 181/Day 1)	1.58 ratio
QIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	A/H1N1 (Day 22/Day 1)	8.11 ratio
QIV/QIV	Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains	B/Victoria (Day 22/Day 1)	5.12 ratio

Secondary

Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)

GMT and 95% CI were analyzed for Day 181 against homologous strains using ANCOVA with study specific covariates. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 181

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
aQIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H1N1	489.45 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H3N2	1423.38 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Yamagata	97.01 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Victoria	128.32 titer
aQIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H3N2	1438.40 titer
aQIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Yamagata	86.43 titer
aQIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Victoria	115.26 titer
aQIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H1N1	411.72 titer
QIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Yamagata	73.37 titer
QIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H3N2	1233.84 titer
QIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Victoria	104.93 titer
QIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H1N1	429.06 titer
QIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Victoria	79.76 titer
QIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H3N2	1222.21 titer
QIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H1N1	307.36 titer
QIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Yamagata	56.57 titer

Comparison: Comparison performed for strain A/H1N1.95% CI: [1.07, 1.32]

Comparison: Comparison performed for strain A/H3N2.95% CI: [0.9, 1.09]

Comparison: Comparison performed for strain B/Yamagata.95% CI: [1.01, 1.25]

Comparison: Comparison performed for strain B/Victoria.95% CI: [0.98, 1.27]

Comparison: Comparison performed for strain A/H1N1.95% CI: [1.3, 1.5]

Comparison: Comparison performed for strain A/H3N2.95% CI: [0.9, 1.1]

Comparison: Comparison performed for strain B/Yamagata.95% CI: [1.2, 1.4]

Comparison: Comparison performed for strain B/Victoria.95% CI: [1.2, 1.5]

Secondary

Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)

Time frame: Day 22

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
aQIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)	A/H1N1	1206.20 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)	A/H3N2	2369.95 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)	B/Yamagata	221.54 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)	B/Victoria	330.94 titer
aQIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)	B/Victoria	244.03 titer
aQIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)	A/H1N1	866.51 titer
aQIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)	B/Yamagata	156.01 titer
aQIV/QIV	Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)	A/H3N2	2229.48 titer

Comparison: Comparison performed for strain A/H1N1.95% CI: [1.28, 1.51]

Comparison: Comparison performed for strain A/H3N295% CI: [0.99, 1.14]

Comparison: Comparison performed for strain B/Yamagata.95% CI: [1.27, 1.58]

Comparison: Comparison performed for strain B/Victoria.95% CI: [1.22, 1.51]

Secondary

Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains

GMT and 95% CI were analyzed for Day 22 for the heterologous strains using ANCOVA with study specific covariates. The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B/ Victoria lineage strain, B/Malaysia/2506/2004.

Time frame: Day 1, Day 22, Day 181

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	A/H3N2 (Day 1)	97.7 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	A/H3N2 (Day 22)	2436.1 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	A/H3N2 (Day 181)	898.1 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	B/Victoria (Day 1)	33.4 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	B/Victoria (Day 22)	327.1 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	B/Victoria (Day 181)	107.1 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	B/Victoria (Day 181)	85.6 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	B/Victoria (Day 1)	23.8 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	A/H3N2 (Day 1)	156.6 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	A/H3N2 (Day 181)	917.6 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	A/H3N2 (Day 22)	2415.2 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	B/Victoria (Day 22)	248.4 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	A/H3N2 (Day 22)	2225.1 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	A/H3N2 (Day 181)	953.2 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	B/Victoria (Day 1)	15.8 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	B/Victoria (Day 181)	77.5 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	B/Victoria (Day 22)	283.2 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	A/H3N2 (Day 1)	40.9 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	B/Victoria (Day 22)	204.8 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	B/Victoria (Day 181)	56.0 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	A/H3N2 (Day 22)	2097.2 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	B/Victoria (Day 1)	15.9 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	A/H3N2 (Day 1)	91.6 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains	A/H3N2 (Day 181)	791.7 titer

Secondary

Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains

To further characterize immune response, MN GMT and 95% CI were analyzed for Day 1, Day 22, and Day 181 against homologous strains. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 1, Day 22, Day 181

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 1)	43.66 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 181)	124.31 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 22)	388.29 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H1N1 (Day 1)	264.36 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 181)	107.05 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H1N1 (Day 181)	727.04 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H3N2 (Day 1)	160.88 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H1N1 (Day 22)	2253.81 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 22)	355.63 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H3N2 (Day 22)	5532.06 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H3N2 (Day 181)	2069.22 titer
aQIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 1)	29.82 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H1N1 (Day 22)	2295.46 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 1)	37.99 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H3N2 (Day 1)	113.74 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 181)	103.59 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 1)	43.13 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 22)	301.39 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H1N1 (Day 1)	198.13 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H3N2 (Day 181)	2127.88 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H3N2 (Day 22)	6649.94 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H1N1 (Day 181)	725.35 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 181)	106.08 titer
aQIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 22)	346.99 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 22)	247.31 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H1N1 (Day 1)	104.28 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H1N1 (Day 22)	2992.29 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H1N1 (Day 181)	686.98 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H3N2 (Day 1)	133.25 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H3N2 (Day 22)	5019.51 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H3N2 (Day 181)	2138.80 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 1)	21.57 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 181)	82.90 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 1)	27.96 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 22)	338.49 titer
QIV/aQIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 181)	95.87 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H3N2 (Day 181)	1696.57 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H3N2 (Day 22)	4696.37 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H1N1 (Day 1)	140.38 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 1)	33.14 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H3N2 (Day 1)	97.47 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H1N1 (Day 181)	412.34 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 181)	60.54 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Victoria (Day 22)	193.09 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 22)	197.51 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 1)	21.07 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	A/H1N1 (Day 22)	1543.54 titer
QIV/QIV	Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains	B/Yamagata (Day 181)	56.03 titer

Secondary

Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains

The percentage of subjects achieving anti-NA titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 after vaccination is reported against homologous strains Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 22, Day 181

Arm	Measure	Group	Value (NUMBER)
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 22)	98.21 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:20 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:640 (Day 22)	85.71 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:40 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:320 (Day 22)	94.64 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:160 (Day 22)	98.21 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:80 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:80 (Day 22)	98.21 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:40 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:160 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:640 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:320 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 22)	91.07 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 181)	89.09 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 181)	72.73 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 181)	92.73 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:40 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 181)	98.18 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 22)	98.21 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:80 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 22)	98.21 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:160 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 181)	94.55 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:640 (Day 181)	70.91 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:320 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:320 (Day 181)	80.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:160 (Day 181)	85.45 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1,≥1:640 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:80 (Day 181)	94.55 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:40 (Day 181)	98.18 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:20 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:20 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 181)	98.33 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 181)	98.33 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 22)	91.80 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 181)	98.33 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:40 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:80 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:160 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:320 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1,≥1:640 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:40 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:80 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:160 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:320 (Day 181)	96.72 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:640 (Day 181)	93.44 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:40 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:80 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:160 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:320 (Day 22)	96.77 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:640 (Day 22)	88.71 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:20 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:40 (Day 181)	98.33 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:80 (Day 181)	98.33 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:160 (Day 181)	95.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:320 (Day 181)	85.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:640 (Day 181)	81.67 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 181)	96.67 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 181)	86.67 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 181)	61.67 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 181)	95.08 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:160 (Day 181)	96.55 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:20 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 181)	95.55 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:40 (Day 181)	89.66 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1,≥1:640 (Day 22)	98.31 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:80 (Day 181)	86.21 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:160 (Day 181)	81.03 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:320 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:320 (Day 181)	67.24 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:640 (Day 181)	55.17 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:160 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:80 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 181)	98.28 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:40 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 181)	91.38 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 181)	84.48 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 181)	51.72 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 22)	89.83 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 181)	96.55 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 22)	96.61 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:320 (Day 181)	93.10 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:640 (Day 181)	72.41 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 181)	96.55 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:40 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:80 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:80 (Day 22)	98.31 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 181)	81.03 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:160 (Day 22)	98.31 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:40 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:320 (Day 22)	94.92 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:640 (Day 22)	79.66 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:20 (Day 181)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:320 (Day 22)	85.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 181)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:20 (Day 181)	90.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1,≥1:640 (Day 22)	85.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:40 (Day 181)	88.33 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 22)	66.67 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 181)	70.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:80 (Day 181)	86.67 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:80 (Day 181)	80.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:320 (Day 22)	88.33 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 181)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 22)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:160 (Day 181)	70.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 22)	98.33 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 181)	96.67 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:160 (Day 22)	90.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:320 (Day 181)	61.67 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:160 (Day 22)	93.33 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 181)	83.33 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:40 (Day 22)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:640 (Day 181)	50.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 22)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 22)	88.33 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 181)	96.67 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:80 (Day 22)	98.33 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 181)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:20 (Day 181)	93.33 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 22)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 22)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 181)	90.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 22)	91.67 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 22)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:40 (Day 22)	98.33 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:320 (Day 181)	70.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:160 (Day 181)	81.67 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 22)	98.33 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 181)	81.67 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:80 (Day 22)	96.67 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:640 (Day 181)	51.67 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 181)	65.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N1, ≥1:40 (Day 181)	91.67 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 181)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	N2, ≥1:640 (Day 22)	68.33 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 181)	40.00 percentage of subjects

Secondary

Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains

The percentage of subjects achieving HI titer ≥1:40 at Day 22 and Day 181 after vaccination and the percentage of subject who experienced seroconversion is reported for homologous strains. Seroconversion was defined in subjects seronegative at baseline (i.e. HI titer \<1:10 on Day 1) as post-vaccination HI titer ≥1:40 and defined in subjects seropositive at baseline (i.e. HI titer ≥1:10 on Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer. The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B/Victoria lineage strain, B/Malaysia/2506/2004.

Time frame: Day 22, Day 181

Arm	Measure	Group	Value (NUMBER)
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	A/H3N2, SCR (Day 22)	78.3 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	A/ H3N2, HI titer ≥1:40 (Day 22)	100 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	A/ H3N2, HI titer ≥1:40 (Day 181)	100 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	B/Victoria, SCR (Day 22)	75.0 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	B/Victoria, HI titer ≥1:40 (Day 22)	98.3 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	B/ Victoria, HI titer ≥1:40 (Day 181)	91.4 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	B/ Victoria, HI titer ≥1:40 (Day 181)	83.6 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	B/Victoria, SCR (Day 22)	82.1 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	A/H3N2, SCR (Day 22)	73.7 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	A/ H3N2, HI titer ≥1:40 (Day 181)	100 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	A/ H3N2, HI titer ≥1:40 (Day 22)	100 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	B/Victoria, HI titer ≥1:40 (Day 22)	100 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	A/ H3N2, HI titer ≥1:40 (Day 22)	100 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	A/ H3N2, HI titer ≥1:40 (Day 181)	100 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	B/Victoria, SCR (Day 22)	81.4 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	B/ Victoria, HI titer ≥1:40 (Day 181)	74.1 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	B/Victoria, HI titer ≥1:40 (Day 22)	96.6 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	A/H3N2, SCR (Day 22)	83.1 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	B/Victoria, HI titer ≥1:40 (Day 22)	98.3 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	B/ Victoria, HI titer ≥1:40 (Day 181)	64.3 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	A/ H3N2, HI titer ≥1:40 (Day 22)	100 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	B/Victoria, SCR (Day 22)	77.6 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	A/H3N2, SCR (Day 22)	69.0 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains	A/ H3N2, HI titer ≥1:40 (Day 181)	98.2 percentage of subjects

Secondary

Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains

The percentage of subjects achieving HI titer ≥1:40 at Day 22 and Day 181 after vaccination is reported against homologous strains. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 22, Day 181

Arm	Measure	Group	Value (NUMBER)
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H1N1 (Day 22)	100 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H1N1 (Day 181)	100 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H3N2 (Day 22)	100 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H3N2 (Day 181)	99.8 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata (Day 22)	98.5 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata (Day 181)	94.3 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Victoria (Day 22)	99.9 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Victoria (Day 181)	95.3 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata (Day 181)	93.9 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata (Day 22)	98.7 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H1N1 (Day 181)	99.2 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Victoria (Day 181)	93.9 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Victoria (Day 22)	100 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H3N2 (Day 181)	100 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H3N2 (Day 22)	100 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H1N1 (Day 22)	100 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Victoria (Day 22)	99.5 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H3N2 (Day 22)	100 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H3N2 (Day 181)	100 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata (Day 22)	98.5 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata (Day 181)	83.9 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Victoria (Day 181)	86.7 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H1N1 (Day 22)	100 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H1N1 (Day 181)	99.2 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H3N2 (Day 22)	100 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H3N2 (Day 181)	98.7 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H1N1 (Day 181)	95.9 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	A/H1N1 (Day 22)	99.7 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata (Day 22)	96.6 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Victoria (Day 181)	76.9 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Victoria (Day 22)	97.9 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata (Day 181)	76.1 percentage of subjects

Secondary

Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains

The percentage of subjects achieving MN titer ≥1:20, ≥1:40, ≥1:80 ≥1:160, ≥1:320 and ≥1:640 at Day 22 and Day 181 after vaccination is reported against homologous strains. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 22, Day 181

Population: The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data (MN titer ≥1:20, ≥1:40, ≥1:80, \>four-fold rise), and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.

Arm	Measure	Group	Value (NUMBER)
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/ H1N1, ≥1:40 (Day 22)	98.31 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:80 (Day 22)	98.31 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:160 (Day 22)	98.31 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:320 (Day 22)	96.61 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:640 (Day 22)	96.61 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:20 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:40 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:80 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:160 (Day 181)	96.67 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:320 (Day 181)	91.67 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:640 (Day 181)	80.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/ H1N1, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:40 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:80 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:160 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:320 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:640 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:20 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:40 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:80 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:160 (Day 181)	96.67 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:320 (Day 181)	91.67 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:640 (Day 181)	86.67 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 22)	98.33 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 22)	95.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 22)	91.67 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 22)	75.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 22)	58.33 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 181)	98.33 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 181)	93.33 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 181)	71.67 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 181)	45.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 181)	25.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 181)	3.33 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 22)	98.31 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 22)	94.92 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 22)	91.53 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 22)	86.44 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 22)	74.58 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 22)	49.15 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 181)	100.00 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 181)	86.67 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 181)	78.33 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 181)	58.33 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 181)	31.67 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 181)	8.33 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:320 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 181)	15.52 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 22)	98.31 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:40 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 181)	8.62 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:20 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 22)	96.61 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 22)	67.80 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 181)	24.14 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 181)	48.28 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 22)	86.44 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:640 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 181)	63.79 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 181)	72.41 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 22)	72.88 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:320 (Day 181)	91.38 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 181)	93.10 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 181)	87.93 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 22)	47.46 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:640 (Day 22)	98.31 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 181)	96.55 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:640 (Day 181)	63.79 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:20 (Day 181)	98.28 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:80 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:320 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:40 (Day 181)	98.28 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 22)	86.44 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 181)	43.10 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 181)	20.69 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:80 (Day 181)	98.28 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:160 (Day 181)	98.28 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:160 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 22)	42.37 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:160 (Day 181)	98.28 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 22)	96.61 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:80 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:160 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:320 (Day 181)	94.83 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:40 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/ H1N1, ≥1:40 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 22)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:640 (Day 181)	86.21 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:80 (Day 181)	100.00 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/ H1N1, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:320 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:40 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 22)	81.67 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:80 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:160 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 181)	12.07 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:640 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 22)	58.33 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:20 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:40 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:80 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:160 (Day 181)	96.55 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 22)	33.33 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:320 (Day 181)	93.10 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:640 (Day 181)	84.48 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 181)	18.97 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 22)	96.67 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 22)	96.67 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 181)	98.28 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 22)	95.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 22)	78.33 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 22)	65.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 22)	31.67 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 181)	74.14 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 181)	93.10 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 181)	79.31 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 181)	56.90 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 181)	32.76 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 181)	44.83 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 181)	15.52 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 181)	5.17 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/ H1N1, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/ H1N1, ≥1:40 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:80 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:160 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:320 (Day 22)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:640 (Day 22)	91.67 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 22)	96.67 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:20 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:40 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 181)	27.59 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:80 (Day 181)	100.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:160 (Day 181)	94.83 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 22)	90.00 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:320 (Day 181)	84.48 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:640 (Day 181)	55.17 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 22)	96.55 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:640 (Day 181)	83.93 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:640 (Day 181)	48.28 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/ H1N1, ≥1:20 (Day 22)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 22)	22.03 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:320 (Day 181)	85.71 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:160 (Day 22)	98.28 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/ H1N1, ≥1:40 (Day 22)	100.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:320 (Day 181)	63.79 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:160 (Day 181)	89.29 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:80 (Day 181)	93.10 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:80 (Day 22)	98.31 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 22)	98.31 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:80 (Day 181)	91.07 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 22)	69.49 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:160 (Day 22)	94.92 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:40 (Day 181)	96.43 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 22)	35.59 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:80 (Day 22)	98.28 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:320 (Day 22)	94.92 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:20 (Day 181)	98.21 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:640 (Day 22)	98.28 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 22)	84.75 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:640 (Day 22)	81.36 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:160 (Day 181)	81.03 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 22)	24.14 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:320 (Day 22)	98.28 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:20 (Day 181)	80.36 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 181)	60.71 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 22)	50.00 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:20 (Day 22)	98.28 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 181)	71.43 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:640 (Day 181)	5.36 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:320 (Day 181)	8.93 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:20 (Day 181)	98.28 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 181)	46.43 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 22)	70.69 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:20 (Day 181)	96.43 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:40 (Day 22)	93.22 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:160 (Day 181)	17.86 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:160 (Day 181)	23.21 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:80 (Day 22)	89.66 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H3N2, ≥1:40 (Day 22)	98.28 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:320 (Day 181)	7.14 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Victoria, ≥1:80 (Day 181)	41.07 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:40 (Day 22)	93.10 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	A/H1N1, ≥1:40 (Day 181)	96.55 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains	B/Yamagata, ≥1:640 (Day 181)	3.57 percentage of subjects

Secondary

Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)

The percentage of subjects achieving seroconversion at Day 22 after vaccination is reported against homologous strains. Seroconversion was defined in subjects seronegative at baseline (i.e. HI titer \<1:10 on Day 1) as postvaccination HI titer ≥1:40 and defined in subjects seropositive at baseline (i.e. HI titer ≥1:10 on Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 1, Day 22

Arm	Measure	Group	Value (NUMBER)
aQIV/aQIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H1N1	62.7 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H3N2	68.9 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Yamagata	76.4 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Victoria	77.4 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H3N2	68.0 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Yamagata	72.0 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Victoria	74.8 percentage of subjects
aQIV/QIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H1N1	60.9 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Yamagata	79.44 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H3N2	72.80 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Victoria	77.92 percentage of subjects
QIV/aQIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H1N1	72.04 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Victoria	69.55 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H3N2	76.74 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	A/H1N1	62.37 percentage of subjects
QIV/QIV	Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)	B/Yamagata	66.49 percentage of subjects

Comparison: Comparison performed for strain A/H1N1.95% CI: [-4.9, 8.6]

Comparison: Comparison performed for strain A/H3N2.95% CI: [-5.6, 7.3]

Comparison: Comparison performed for strain B/Yamagata.95% CI: [-1.8, 10.4]

Comparison: Comparison performed for strain B/Victoria.95% CI: [-3.3, 8.5]

Comparison: Comparison performed for strain A/H1N1.95% CI: [3.11, 16.17]

Comparison: Comparison performed for strain A/H3N2.95% CI: [-10.02, 2.15]

Comparison: Comparison performed for strain B/Yamagata.95% CI: [6.73, 19.12]

Comparison: Comparison performed for strain B/Victoria.95% CI: [2.17, 14.54]

Secondary

Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains

The percentage of subjects achieving HI Titers ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 at Day 22 after vaccination is reported against homologous strains. Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.

Time frame: Day 22

Arm	Measure	Group	Value (NUMBER)
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:110	93.0 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:151	87.6 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:330	97.3 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:629	27.9 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:215	69.9 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:110	100.0 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:330	44.0 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:151	100.0 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:330	58.7 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/ H1N1 ≥1:629	94.8 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:110	99.8 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:215	79.6 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:151	99.8 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:629	45.3 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:215	99.5 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:215	99.8 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:151	91.3 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:330	99.3 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:629	99.0 percentage of subjects
aQIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:110	90.8 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:110	89.9 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:110	88.4 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:330	48.7 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:629	20.9 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:110	100.0 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:151	81.6 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:110	100.0 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:629	37.6 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:629	99.7 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:215	64.2 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:151	100.0 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:330	34.3 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:330	99.7 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:330	93.7 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:151	87.9 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:215	99.2 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:215	100.0 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/ H1N1 ≥1:629	87.6 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:151	100.0 percentage of subjects
aQIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:215	73.4 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:215	53.3 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:110	99.7 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:151	99.5 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:215	97.5 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:330	93.2 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/ H1N1 ≥1:629	87.9 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:110	100.0 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:151	100.0 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:215	100.0 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:330	99.5 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:629	99.2 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:110	82.7 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:151	75.9 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:330	25.1 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:629	14.2 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:110	86.0 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:151	83.0 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:215	67.5 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:330	41.9 percentage of subjects
QIV/aQIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:629	34.3 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:629	95.1 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:330	95.9 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:330	32.0 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:110	76.1 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:215	97.7 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:151	99.5 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:151	97.4 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:151	70.6 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H3N2, HI ≥1:110	99.5 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/ H1N1 ≥1:629	74.2 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:110	97.7 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:215	53.0 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:330	82.5 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:215	38.5 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	A/H1N1, HI ≥1:215	93.8 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:330	14.9 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:151	59.9 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:110	68.3 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Victoria, HI ≥1:629	24.1 percentage of subjects
QIV/QIV	Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains	B/Yamagata, HI ≥1:629	7.3 percentage of subjects

Secondary

Safety Endpoint: Percentage of Subjects With Diagnosis of Failure to Thrive or Short Stature

Safety of revaccination was assessed in terms of percentage of subjects reporting diagnosis of failure to thrive or short stature up to 12 months after last vaccination.

Time frame: Day 1 to Day 366

Population: The unsolicited safety set consisting of all subjects who received a study vaccination with documented safety assessments for unsolicited AE data (including those where it was reported/confirmed that no events had occurred).

Arm	Measure	Value (NUMBER)
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Diagnosis of Failure to Thrive or Short Stature	0.25 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Diagnosis of Failure to Thrive or Short Stature	0.74 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Diagnosis of Failure to Thrive or Short Stature	0.25 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Diagnosis of Failure to Thrive or Short Stature	0.76 percentage of subjects

Secondary

Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness

Safety of revaccination was assessed in terms of percentage of subjects reporting otitis media, or pneumonia, or influenza-like illness up to 12 months after last vaccination.

Time frame: Day 1 to Day 366

Arm	Measure	Group	Value (NUMBER)
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	otitis media, any event	3.23 percentage of subjects
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	influenza-like illness	7.94 percentage of subjects
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	pneumonia, any event	1.49 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	otitis media, any event	3.47 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	influenza-like illness	10.17 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	pneumonia, any event	1.49 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	pneumonia, any event	0.75 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	otitis media, any event	3.73 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	influenza-like illness	9.20 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	otitis media, any event	2.80 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	influenza-like illness	7.89 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness	pneumonia, any event	1.78 percentage of subjects

Secondary

Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.

Safety of revaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCD, AESI and medically attended AE. Each subject was followed for a period of 12 months after receipt of the study vaccine. NOCDs include AEs that represents a new diagnosis of a chronic medical condition that was not present or suspected in a subject prior to study enrollment. AESIs include potentially immune-mediated disorders which were reported by the investigators.

Time frame: Day 1 to Day 366

Population: The unsolicited safety set consisting of all subjects who received a study vaccination with documented safety assessments for unsolicited adverse event (AE) data (including those where it was reported/confirmed that no events had occurred).

Arm	Measure	Group	Value (NUMBER)
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	NOCD	0.50 percentage of subjects
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	SAE	2.48 percentage of subjects
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	AESI	0 percentage of subjects
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	AE leading to withdrawal	0 percentage of subjects
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	Medically attended AE	51.61 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	AE leading to withdrawal	0 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	NOCD	0 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	AESI	0 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	SAE	2.73 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	Medically attended AE	54.34 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	AE leading to withdrawal	0 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	Medically attended AE	53.98 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	SAE	1.74 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	NOCD	0 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	AESI	0 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	NOCD	0 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	SAE	2.04 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	Medically attended AE	48.60 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	AE leading to withdrawal	0 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.	AESI	0.25 percentage of subjects

Secondary

Safety Endpoint: Percentage of Subjects With Solicited AEs

Safety of revaccination was assessed in terms of percentage of subjects reporting solicited AEs up to 7 days after vaccination.

Time frame: Day 1 to Day 7 after vaccination

Population: The solicited safety set consisting of all subjects who received a study vaccination with evaluable solicited AE data recorded on a diary card.

Arm	Measure	Group	Value (NUMBER)
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Solicited Systemic AE	39.21 percentage of subjects
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Solicited Local AE	44.67 percentage of subjects
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Other (analgesic/antipyretic use)	27.54 percentage of subjects
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Any Solicited AE	64.76 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Solicited Local AE	37.97 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Other (analgesic/antipyretic use)	10.17 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Any Solicited AE	50.12 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Solicited Systemic AE	24.81 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Any Solicited AE	53.48 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Other (analgesic/antipyretic use)	16.92 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Solicited Systemic AE	30.85 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Solicited Local AE	36.82 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Other (analgesic/antipyretic use)	10.43 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Any Solicited AE	40.71 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Solicited Local AE	29.52 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Solicited AEs	Solicited Systemic AE	18.83 percentage of subjects

Secondary

Safety Endpoint: Percentage of Subjects With Unsolicited AEs

Safety of revaccination was assessed in terms of percentage of subjects reporting unsolicited AEs during the overall study period (Day 1 to Day 366).

Time frame: Day 1 to Day 366

Arm	Measure	Group	Value (NUMBER)
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Unsolicited AEs	Any Unsolicited AE	54.09 percentage of subjects
aQIV/aQIV	Safety Endpoint: Percentage of Subjects With Unsolicited AEs	Related Unsolicited AE	6.20 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Unsolicited AEs	Related Unsolicited AE	3.97 percentage of subjects
aQIV/QIV	Safety Endpoint: Percentage of Subjects With Unsolicited AEs	Any Unsolicited AE	55.33 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Unsolicited AEs	Any Unsolicited AE	55.97 percentage of subjects
QIV/aQIV	Safety Endpoint: Percentage of Subjects With Unsolicited AEs	Related Unsolicited AE	5.72 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Unsolicited AEs	Any Unsolicited AE	52.16 percentage of subjects
QIV/QIV	Safety Endpoint: Percentage of Subjects With Unsolicited AEs	Related Unsolicited AE	3.82 percentage of subjects

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis

Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis

Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains

Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains

Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains

Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains

Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains

Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)

Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)

Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains

Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains

Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains

Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains

Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains

Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains

Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)

Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains

Safety Endpoint: Percentage of Subjects With Diagnosis of Failure to Thrive or Short Stature

Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness

Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.

Safety Endpoint: Percentage of Subjects With Solicited AEs

Safety Endpoint: Percentage of Subjects With Unsolicited AEs